Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Acrotech Biopharma Inc.
Chipscreen Biosciences, Ltd.
National Cancer Institute (NCI)
National Cancer Institute (NCI)